John H. Barton

1.1k total citations
32 papers, 885 citations indexed

About

John H. Barton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, John H. Barton has authored 32 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in John H. Barton's work include Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (7 papers). John H. Barton is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (9 papers) and Lung Cancer Treatments and Mutations (7 papers). John H. Barton collaborates with scholars based in United States, United Kingdom and Japan. John H. Barton's co-authors include John D. Hainsworth, F. Anthony Greco, Sharlene Litchy, James E. Bradof, Howard A. Burris, Gerry Ann Houston, Robert C. Hermann, David R. Spigel, Lisa H. Morrissey and Dianna Shipley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

John H. Barton

31 papers receiving 858 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John H. Barton United States	15	526	350	284	244	180	32	885
James E. Bradof United States	13	547 1.0×	322 0.9×	272 1.0×	234 1.0×	110 0.6×	19	874
Don W. Shaffer United States	8	407 0.8×	273 0.8×	151 0.5×	151 0.6×	138 0.8×	11	678
Oliver Rosen United States	10	689 1.3×	221 0.6×	412 1.5×	123 0.5×	217 1.2×	19	1.3k
Dianna Shipley United States	20	724 1.4×	288 0.8×	453 1.6×	61 0.3×	283 1.6×	68	1.1k
Xiaopei Zhu United States	15	354 0.7×	172 0.5×	484 1.7×	68 0.3×	344 1.9×	22	1.1k
Robert J. Behrens United States	14	484 0.9×	183 0.5×	143 0.5×	110 0.5×	206 1.1×	40	817
Marta Orsenigo Italy	16	802 1.5×	279 0.8×	588 2.1×	40 0.2×	296 1.6×	25	1.4k
Lydia Sánchez-Verde Spain	18	394 0.7×	439 1.3×	100 0.4×	155 0.6×	465 2.6×	21	977
Giovanna De Maglio Italy	15	308 0.6×	143 0.4×	364 1.3×	77 0.3×	238 1.3×	48	815
Robert N. Raju United States	16	667 1.3×	127 0.4×	241 0.8×	70 0.3×	284 1.6×	30	985

Countries citing papers authored by John H. Barton

Since Specialization

Citations

This map shows the geographic impact of John H. Barton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Barton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Barton more than expected).

Fields of papers citing papers by John H. Barton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Barton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Barton. The network helps show where John H. Barton may publish in the future.

Co-authorship network of co-authors of John H. Barton

This figure shows the co-authorship network connecting the top 25 collaborators of John H. Barton. A scholar is included among the top collaborators of John H. Barton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John H. Barton. John H. Barton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kubicki, Tadeusz, Mandar S. Bhagwat, John H. Barton, et al.. (2024). Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients. Blood. 144(Supplement 1). 3335–3335.

Burris, Howard A., Jeffrey R. Infante, F. Anthony Greco, et al.. (2016). A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle. Cancer Chemotherapy and Pharmacology. 77(5). 1079–1086. 22 indexed citations

Bendell, Johanna C., Suzanne F. Jones, Lowell L. Hart, et al.. (2014). A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Investigational New Drugs. 33(1). 187–193. 32 indexed citations

Yardley, Denise A., Howard A. Burris, Bobby L. Clark, et al.. (2011). Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Breast Cancer. 11(3). 146–152. 24 indexed citations

Burris, Howard A., Suzanne F. Jones, Dianna Shipley, et al.. (2010). Phase II Study of Capecitabine in Combination With Thalidomide in Patients With Metastatic Breast Cancer. Cancer Investigation. 28(4). 408–412. 5 indexed citations

Spigel, David R., John D. Hainsworth, John H. Barton, et al.. (2010). Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 841–845. 5 indexed citations

Hainsworth, John D., David R. Spigel, Howard A. Burris, et al.. (2010). Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site. Cancer. 116(10). 2448–2454. 14 indexed citations

Yardley, Denise A., Howard A. Burris, F. Anthony Greco, et al.. (2009). Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer. 9(3). 178–183. 21 indexed citations

Yardley, Denise A., Howard A. Burris, David R. Spigel, et al.. (2009). A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer. Clinical Breast Cancer. 9(4). 247–252. 12 indexed citations

10.

Barton, John H., Dianna Shipley, Edward Arrowsmith, et al.. (2009). Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer. Journal of Clinical Oncology. 27(15_suppl). 1091–1091. 5 indexed citations

11.

Jones, Suzanne F., Dana S. Thompson, John H. Barton, et al.. (2008). A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 9(3). 154–159. 11 indexed citations

12.

Hainsworth, John D., David R. Spigel, John H. Barton, et al.. (2008). Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma. Cancer. 113(4). 765–771. 25 indexed citations

13.

Yardley, Denise A., Howard A. Burris, C. Farley, et al.. (2008). A Phase II Feasibility Trial of Dose-Dense Docetaxel Followed by Doxorubicin/Cyclophosphamide as Adjuvant or Neoadjuvant Treatment for Women with Node-Positive or High-Risk Node-Negative Breast Cancer. Clinical Breast Cancer. 8(3). 242–248. 8 indexed citations

14.

Yardley, Denise A., Howard A. Burris, Lisa Simons, et al.. (2008). A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 8(5). 425–431. 30 indexed citations

15.

Hainsworth, John D., Anthony A. Meluch, David R. Spigel, et al.. (2007). Weekly Docetaxel and Bortezomib as First-Line Treatment for Patients with Hormone-Refractory Prostate Cancer: A Minnie Pearl Cancer Research Network Phase II Trial. Clinical Genitourinary Cancer. 5(4). 278–283. 36 indexed citations

16.

Greco, F. Anthony, David R. Spigel, John H. Barton, et al.. (2006). Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 24(18_suppl). 7547–7547. 6 indexed citations

17.

Barton, John H., William H. Liggett, Mark Mainwaring, et al.. (2006). Phase II pilot trial of imatinib mesylate with weekly docetaxel in metastatic breast cancer. Journal of Clinical Oncology. 24(18_suppl). 10716–10716. 5 indexed citations

18.

Peacock, N. W., James D. Bearden, F. Anthony Greco, et al.. (2005). Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 704–704. 6 indexed citations

19.

Greco, F. Anthony, Howard A. Burris, Sharlene Litchy, et al.. (2002). Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology. 20(6). 1651–1656. 85 indexed citations

20.

Hainsworth, John D., Howard A. Burris, Sharlene Litchy, et al.. (2000). Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer. 89(2). 328–333. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact